bioAffinity Technologies, Inc.
No SEC Form 4 filings for $BIAF in the last 30 days.
See all $BIAF insider activity →bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into effective as of August 12, 2026, between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and each pur
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and a
bioAffinity Technologies (Nasdaq: BIAF) said it will partner with Pictor, Inc. to develop and commercialize next-generation asthma and COPD diagnostics. The collaboration combines bioAffinity flow cytometry with Pictor targeted proteomic cytokine profiling, with tests expected to launch as CLIA Laboratory Developed Tests. bioAffinity will own IP for the tests; Pictor retains its platform IP.
Over the past 7 days, alphai's AI scored 1 news story mentioning BIAF (bioAffinity Technologies, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BIAF coverage spans financial news, corporate actions and earnings.
The filing indicates a new equity-linked financing (unregistered sales plus warrants), which can be dilutive and may pressure near-term valuation until terms are digested.
The filing provides fresh operating momentum metrics plus cash and expense trajectory, which can drive near-term sentiment and valuation for BIAF.
The deal is a commercialization and development catalyst for bioAffinity’s lung inflammation diagnostics, but it is pre-offering (LDT) with no clinical readouts or financial terms disclosed.
The filing signals a new capital-raising/financing transaction structure, which can affect dilution expectations and near-term liquidity/risk.
The approval of major equity plans, offerings, and a reverse split by bioAffinity Technologies (BIAF) indicates strategic flexibility for capital management. While these actions can support growth and incentivize employees, they may also lead to share dilution, which could exert downward pressure on the stock price in the short term.
alphai scores every news story that mentions BIAF with an AI model for sentiment and relevance, and aggregates insider trades from bioAffinity Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into effective as of August 12, 2026, between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and each pur
6 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and a
6 min readbioAffinity Technologies (Nasdaq: BIAF) said it will partner with Pictor, Inc. to develop and commercialize next-generation asthma and COPD diagnostics. The collaboration combines bioAffinity flow cytometry with Pictor targeted proteomic cytokine profiling, with tests expected to launch as CLIA Laboratory Developed Tests. bioAffinity will own IP for the tests; Pictor retains its platform IP.
3 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is entered into and made effective as of June 16, 2026, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and eac
6 min readbioAffinity Technologies' stockholders approved several significant proposals at their 2026 Annual Meeting. Key approvals include expanding the 2024 Equity Incentive Compensation Plan to 1,000,000 shares, authorizing potential non-public offerings, and allowing a discretionary reverse stock split ranging from 1-for-2 to 1-for-250. These actions provide the company with substantial flexibility for future compensation, fundraising, and capital structure adjustments, although they also introduce potential share dilution.
2 min readbioAffinity Technologies (BIAF) released a case study demonstrating how its CyPath® Lung diagnostic test helped a physician defer an unnecessary biopsy for a patient with a suspicious pulmonary nodule. Despite imaging and risk models suggesting a high likelihood of cancer, the noninvasive sputum-based test indicated "Unlikely Malignancy," leading to a follow-up scan that showed the nodule had resolved. This highlights CyPath® Lung's potential to provide objective data for managing indeterminate lung nodules, especially in high-risk patients where invasive procedures carry significant risks.
3 min readbioAffinity Technologies has expanded its Medical and Scientific Advisory Board with the appointment of three new members: Drs. David Ost, Daniel Sterman, and J. Scott Ferguson. These appointments aim to align the board with the company's clinical, scientific, and commercial priorities, particularly for its noninvasive lung cancer diagnostic test, CyPath Lung. The new members are highly respected leaders in pulmonary medicine and lung cancer care, and their expertise will support the integration and adoption of CyPath Lung for early lung cancer detection.
3 min readbioAffinity Technologies has commenced a large-scale, 2,000-patient longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test designed to detect early-stage lung cancer. The study aims to evaluate the clinical performance of the flow cytometry test using sputum samples from high-risk individuals with existing lung nodules. This trial seeks to establish CyPath Lung as a standard of care for early-stage lung cancer assessment, leveraging its reported 92% sensitivity, 87% specificity, and 88% accuracy from previous trials.
4 min readbioAffinity Technologies (BIAF) has expanded its Medical and Scientific Advisory Board by adding three prominent lung cancer specialists: David Ost, Daniel Sterman, and J. Scott Ferguson. This move is aimed at strengthening the clinical and scientific strategy for its noninvasive CyPath Lung test, which is designed for early lung cancer detection in high-risk patients. The company seeks to drive broader adoption and clinical integration of CyPath Lung, positioning it as a potential standard-of-care tool.
2 min readbioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
4 min read
